Q-omics provides the consensus-scored TMEM116 profile across patient tissues and cancer cell-line models. TMEM116 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM116 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMEM116 RNA expression shows 19,896 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where TMEM116 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM116 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM116 survival associations across molecular data types. TMEM116 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM116 RNA expression–survival associations across cancer types. High TMEM116 expression shows unfavorable associations in UVM, LIHC and STAD, but favorable associations in UCS, KIRP and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM116 RNA expression.
This table summarizes TMEM116 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM116. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM116 shows lower tumor expression in KIRC, THCA, LUAD and KIRP and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher TMEM116 RNA expression in normal versus tumor tissue (log2 FC = −1.306, t-test p < 0.001).
This table shows molecular features associated with TMEM116 in patient tissues and cancer cell lines. In patient samples, TMEM116 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM116 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and STOMACH.
